Display options
Share it on

J Cancer Res Clin Oncol. 1995;121(6):338-42. doi: 10.1007/BF01225685.

The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes.

Journal of cancer research and clinical oncology

W Verbeek, K Vehmeyer, B Wörmann, W Hiddemann

Affiliations

  1. Department of Hematology/Oncology, Faculty of Medicine, Georg-August University Göttingen, Germany.

PMID: 7797598 DOI: 10.1007/BF01225685

Abstract

An inherent defect of erythroid differentiation at the colony-forming unit blast (CFU-blast) compartment and (or) an impaired response of early erythroid progenitors (BFU-E) to growth stimulation are both considered to contribute to anemia in myelodysplastic syndromes (MDS). With the intention of improving survival and growth of early erythroid progenitors we investigated the effect of stem-cell factor (SCF) and interleukin-3 (IL-3) alone and in combination with erythropoietin, on the in vitro erythropoiesis of 13 patients with MDS and of three normal controls. SCF and IL-3 alone did not promote erythroid colony growth in MDS, while 3 cases responded to erythropoietin alone. In each of these, BFU-E colony growth could be increased by SCF, which was also found in all normal bone marrows. Altogether 6 cases showed a significant enhancement of BFU-E colony numbers by the combination of SCF and erythropoietin as compared to erythropoietin alone (P = 0.036). Out of the 6 responding cases, 5 belonged to the FAB-classified subgroups refractory anemia (RA) and refractory anemia with ringed sideroblasts (RA/RS) (5/5), while 1 patient was classified as having refractory anemia with excess of blasts (RAEB) (1/4). No patient with refractory anemia with excess of blasts in transformation (RAEB-T) (0/4) responded. In spite of these positive effects, the absolute number of BFU-E colonies remained reduced in all MDS cases when compared to normal controls. IL-3 proved ineffective in increasing the response to erythropoietin in MDS although it increased erythropoietin-induced BFU-E formation in normal controls significantly. We conclude that the striking synergistic effect of SCF and erythropoietin on erythroid colony formation seen with normal bone marrow is conserved in most cases with RA and RA/RS. In RAEB and RAEB-T the intrinsic defect of the erythroid differentiation pathway cannot be overcome by SCF.

References

  1. J Clin Oncol. 1991 Jul;9(7):1241-50 - PubMed
  2. Acta Haematol. 1983;70(1):1-10 - PubMed
  3. Blood. 1990 Aug 1;76(3):455-62 - PubMed
  4. Blood. 1991 Sep 15;78(6):1403-12 - PubMed
  5. Blood. 1991 Jun 1;77(11):2316-21 - PubMed
  6. Exp Hematol. 1991 Mar;19(3):226-31 - PubMed
  7. Cell. 1990 Oct 5;63(1):195-201 - PubMed
  8. Leukemia. 1991 Apr;5(4):340-6 - PubMed
  9. Blood. 1992 Dec 15;80(12):3000-8 - PubMed
  10. Leukemia. 1990 Nov;4(11):771-4 - PubMed
  11. Leuk Res. 1990;14(3):247-53 - PubMed
  12. Leuk Res. 1989;13(3):245-51 - PubMed
  13. Blood. 1991 May 15;77(10):2142-9 - PubMed
  14. Semin Hematol. 1986 Oct;23(4):284-99 - PubMed
  15. Blood. 1992 Sep 1;80(5):1199-206 - PubMed
  16. Br J Haematol. 1982 Jun;51(2):189-99 - PubMed
  17. Leukemia. 1993 Jan;7(1):75-9 - PubMed
  18. Exp Hematol. 1990 Dec;18(11):1204-8 - PubMed
  19. Br J Haematol. 1989 Oct;73(2):158-64 - PubMed
  20. Blood. 1992 Jun 15;79(12):3196-202 - PubMed
  21. Blood. 1991 Oct 1;78(7):1658-63 - PubMed
  22. Blood. 1991 Nov 1;78(9):2216-21 - PubMed
  23. Blood. 1992 Sep 1;80(5):1213-7 - PubMed
  24. Blood. 1992 Jul 15;80(2):382-7 - PubMed

Substances

MeSH terms

Publication Types